Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Cork

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The British Journal of Dermatology|January 29, 2000
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapyJ I Harper, I Ahmed, G Barclay, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2019
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinionJ P Thyssen, M S de Bruin-Weller, A S Paller, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 18, 2020
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenA Wollenberg, S Christen-Zäch, A Taieb, et al.
The British Journal of Dermatology|June 7, 2019
Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosisJ K Simpson, M Martinez-Queipo, A Onoufriadis, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2020
European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitisJ P Thyssen, C Vestergaard, M Deleuran, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The British Journal of Dermatology|January 29, 2000
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapyJ I Harper, I Ahmed, G Barclay, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2019
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinionJ P Thyssen, M S de Bruin-Weller, A S Paller, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 18, 2020
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenA Wollenberg, S Christen-Zäch, A Taieb, et al.
The British Journal of Dermatology|June 7, 2019
Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosisJ K Simpson, M Martinez-Queipo, A Onoufriadis, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2020
European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitisJ P Thyssen, C Vestergaard, M Deleuran, et al.
Pageof 8